Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 12, 2002, Pages 5545-5552

  Saveanu, A ^a   Lavaque, E ^a   Gunz, G ^a   Barlier, A ^a   Kim, S ^b   Taylor, J E ^b   Culler, M D ^b   Enjalbert, A ^a   Jaquet, Philippe ^a  

^a CNRS   (France)

^b Biomeasure Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; BIM 23023; BIM 23454; BIM 23A387; BIM 53097; DOPAMINE DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; PROLACTIN; QUINAGOLIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SULPIRIDE; UNCLASSIFIED DRUG;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HORMONE INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROLACTIN RELEASE; TUMOR CELL CULTURE;

ADENOMA; ADULT; AMINOQUINOLINES; CELLS, CULTURED; DOPAMINE AGONISTS; DRUG SYNERGISM; FEMALE; HORMONES; HUMAN GROWTH HORMONE; HUMANS; MALE; OCTREOTIDE; PEPTIDES, CYCLIC; PITUITARY NEOPLASMS; PROLACTIN; PROTEIN ISOFORMS; RECEPTORS, DOPAMINE D2; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER; SOMATOSTATIN;

EID: 0036929913     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-020934     Document Type: Article

References (36)

1. Stewart PM 2000 Current therapy for acromegaly. Trends Endocrinol Metab 11:128-132
2. Sassolas G, Harris AG, James-Deidier A 1990 Long-term effect of incremental doses of the somatostatin analog SMS-201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group. J Clin Endocrinol Metab 71:391-397
3. Vance ML, Harris AG 1995 Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Arch Intern Med 151:1573-1578
4. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibansky A, Molitch ME, Gagel RF, Boyd AE, Sheeler L, Cook D, Malarkey WB, Jackson IM, Vance ML, Thorner MD, Ho PJ, Jaffe CA, Frohman LA, Kleenberg DL 1995 Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients. A clinical center research study. J Clin Endocrinol Metab 80:2768-2775
5. Flogstad AK, Halse J, Haldorsen T, Lancranjan I, Marbach P, Bruns C, Jervell J 1995 Sandostatin LAR in acromegalic patients: A dose-range study. J Clin Endocrinol Metab 80:3601-3607
6. Caron P, Morange-Ramos I, Cogne M, Jaquet P 1997 Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 82:18-22
7. Jaffe CA, Barkan AL 1992 Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 21:713-735
8. Lamberts SWJ, Verleun T, Hofland L, Del Pozo E 1987 A comparison between the effects of SMS201-995, bromocriptine and the combination of both drugs on hormone release by cultured pituitary tumor cells of acromegalic patients. Clin Endocrinol (Oxf) 27:11-23
9. Jaquet P 1997 Evidence for dopamine agonists in the treatment of acromegaly. J Endocrinol 155:59-60
10. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC 2000 Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity. Science 288:154-157
11. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A, Ouafik LH 2000 Human somatostatin receptors subtypes in acromegaly: Distinct patterns of messenger ribonucleic acid expression and hormone suppression identify distinct tumoral phenotypes. J Clin Endocrinol Metab 85:781-792
12. Jaquet P, Gunz G, Grisoli F 1985 Hormonal regulation of prolactin release by human prolactinoma cells cultured in serum-free conditions. Horm Res 22: 153-163
13. Tulipano G, Soldi D, Bagnasco M, Culler MD, Taylor JE, Cocchi J, Giustina A 2002 Characterization of new selective somatosta tin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology 143:1218-1224
14. Barlier A, Pellegrini-Bouiller I, Gunz G, Zamora AJ, Jaquet P, Enjalbert A 1999 Impact of gsp oncogene on the expression of genes coding for Gsa, Pit-1, Gi2a, and somatostatin receptor 2 in human somatotroph adenomas: Involvement in octreotide sensitivity. J Clin Endocrinol Metab 84:2759-2765
15. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, Coy DH, Culler MD, Melmed S 1997 Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SST2 and SST5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 99: 789-798
16. Wagenaar AH, Harris AG, Van der Lely AJ, Lamberts SWJ 1991 Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly. Acta Endocrinol (Copenh) 125: 637-642
17. Flogstad AK, Halse J, Grass P, Abish E, Djoseland O, Kutz K, Bodd E, Jervell J 1994 A comparison of octreotide, bromocriptine or a combination of both drugs m acromegaly. J Clin Endocrinol Metab 79:461-465
18. Chiodini PG, Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Petroncini M, Liuzzi A, Del Pozo E 1987 Medical treatment of acromegaly with SMS201-995, a somatostatin analog: A comparison with bromocriptine. J Clin Endocrinol Metab 64:447-453
19. Halse J, Harris AG, Kvitsborg A, Kjartansson O, Hanssen E, Smiseth O, Djosland O, Hass G, Jervell J 1990 A randomized study of SMS201-995 versus bromocriptine treatment in acromegaly: Clinical and biochemical effects. J Clin Endocrinol Metab 70:1254-1261
20. Li JK, Chow CC, Yeung VT, Mak TW, Ko GT, Swaminathan R, Chan JC, Cockram CS 2000 Treatment of chinese acromegaly with a combination of bromocriptine and octreotide. Aust N Z J Med 30:457-461
21. Fredstorp L, Kutz K, Werner S 1994 Treatment with octreotide and bromocriptine in patients with acromegaly: An open pharmacodynamic interaction study. Clin Endocrinol (Oxf) 41:103-108
22. Lombardi G, Colao AM, Ferone D, Sarnacchiaro F, Marzullo P, Di Sarno A, Rossi E, Merola B 1995 CV205-502 treatment in therapy-resistant acromegalic patients. Eur J Endocr 132:559-564
23. Marzullo P, Ferone D, Di Somma C, Pivonello R, Fillipella M, Lombardi G, Colao AM 1999 Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1:115-120
24. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A 1998 Cabergoline in the treatment of acromegaly: A study in 64 patients. J Clin Endocrinol Metab 83:374-378
25. Herbert TE, Bouvier M 1998 Structural and functional aspects of G protein-coupled receptor oligomerization. Biochem Cell Biol 76:1-11
26. Angers S, Salahpour A, Bouvier M 2002 Dimerization: An emerging concept for G protein-coupled receptor ontogeny and function. Armu Rev Pharmacol Toxicol 42:409-435
27. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC 2000 Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 275:7862-7869
28. Pfeiffer M, Koch T, Schroder H, Klutzny M, Kirscht S, Kreienkamp HJ, Hollt V, Schulz S 2001 Homo- and heterodimerization of somatostatin receptor subtypes. J Biol Chem 276:14027-14036
29. Zawarynski P, Tallerico T, Seeman P, Lee SP, O'Dowd BF, George SR 1998 Dopamine D2 receptor dimers m human and rat brain. FEBS Lett 441:383-386
30. Scarselli M, Novi F, Schallmach E, Lin R, Baragli A, Colzi A, Griffon N, Corsini GU, Sokoloff P, Lavenson R, Vogel Z, Maggio R 2001 D2-D3 dopamine receptor heterodimers exhibit unique functional properties. J Biol Chem 276:30308-30314
31. Jordan BA, Devi LA 1999 G protein-coupled receptor heterodimerization modulates receptor function. Nature 399:697-700
32. George SR, Fan TH, Xie Z, Tse R, Tam V, Varghese G, O'Dowd BF 2000 Oligomerization of μ-and δ-opioid receptors. J Biol Chem 275:26128-26135
33. B receptors-the first 7TM heterodimers. Trends Pharmacol Sci 20:396-399
34. B heterodimer as the functional receptor. J Pharmacol Exp Ther 293: 460-467
35. Thapar K, Kovacs K, Laws ER, Muller PJ 1993 Pituitary adenomas: Current concepts in classification, histopathology, and molecular biology. The Endocrinologist 3:39-57
36. 2 receptor gene expression. J Clin Endocrinol Metab 81:3390-3396